Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.

A highly aggressive human CALLA+C mu+ pre-B acute lymphoblastic leukemia (ALL) cell line (NALM-6-UM1) causes disseminated and invariably fatal leukemia in CB.17 mice with severe combined immunodeficiency (SCID). We used this SCID mouse model of human pre-B ALL to evaluate and compare, in a total of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. B43-PAP plus CPA was superior to either the immunotoxin or drug alone, and combined immunochemotherapy markedly improved the event-free survival (EFS) of SCID mice challenged with NALM-6-UM1 pre-B ALL cells. Notably, 90% to 100% of SCID mice challenged with 1 x 10(6) leukemia cells and then treated with B43-PAP plus CPA combined immunochemotherapy regimens became long-term survivors, a result not achieved with B43-PAP alone or CPA alone. The advantage was particularly evident in mice inoculated with 5 x 10(6) leukemia cells. While neither 15 micrograms B43-PAP (median survival, 58 days) nor 1 mg CPA (median survival, 49 days) resulted in long-term EFS of SCID mice challenged with 5 x 10(6) NALM-6-UM1 pre-B ALL cells, the probability of EFS at 6 months was 50% +/- 16% for SCID mice treated with 15 micrograms B43-PAP plus 1 mg CPA (median survival, greater than 180 days) (P less than .0001). The probability of long-term EFS was only 14% +/- 7% for mice treated with 30 micrograms B43-PAP and 0% +/- 0% for mice treated with 1 mg CPA, but 40% +/- 16% for mice treated with 30 micrograms B43-PAP plus 1 mg CPA (P less than .0001). Similarly, the probability of EFS at 6 months was 40% +/- 16% for mice treated with 2 mg CPA alone, 70% +/- 15% for mice treated with 2 mg CPA plus 15 micrograms B43-PAP, and 70% +/- 15% for mice treated with 2 mg CPA plus 30 micrograms B43-PAP. Ten SCID mice in the B43-PAP plus CPA combined immunochemotherapy arms surviving long term after the inoculation of 5 x 10(6) NALM-6-UM1 pre-B ALL cells were electively killed at 174 to 181 days to assess their leukemia burden. We found no evidence of leukemia in any of the bone marrow specimens by two-color immunofluorescence and multiparameter flow cytometry.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  F. Uckun,et al.  Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia , 1986, The Journal of experimental medicine.

[2]  R. Gale,et al.  Acute lymphoblastic leukemia: recent advances in biology and therapy. , 1989, Blood.

[3]  F. Uckun.  Regulation of human B-cell ontogeny. , 1990, Blood.

[4]  E. Vitetta,et al.  Redesigning nature's poisons to create anti-tumor reagents. , 1987, Science.

[5]  J. Uhr,et al.  Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. , 1988, Cancer research.

[6]  F. Uckun,et al.  Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. , 1985, Journal of immunology.

[7]  J. Ledbetter,et al.  Immunobiologic differences between normal and leukemic human B-cell precursors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[9]  M. Cooper,et al.  Pre-B cell leukemia responds poorly to treatment: a pediatric oncology group study. , 1984, Blood.

[10]  R. Collins,et al.  Phase I immunotoxin trial in patients with B-cell lymphoma. , 1991, Cancer research.

[11]  J. Kersey,et al.  Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. , 1987, Blood.

[12]  D. Neville,et al.  Monoclonal Antibody‐Ricin or Ricin A Chain Hybrids: Kinetic Analysis of Cell Killing for Tumor Therapy , 1982, Immunological reviews.

[13]  N. Sládek,et al.  Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. , 1985, Cancer research.

[14]  F. Uckun,et al.  Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. , 1985, Cancer research.

[15]  M. Greaves.  Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia. , 1981, Cancer research.

[16]  D. Arthur,et al.  In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1992, Blood.

[17]  Cytogenetic features and serum lactic dehydrogenase level predict a poor treatment outcome for children with pre-B-cell leukemia. , 1986, Blood.

[18]  P. Thorpe,et al.  The Preparation and Cytotoxic Properties of Antibody‐Toxin Conjugates , 1982, Immunological reviews.

[19]  Sm Hus.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures , 1981 .

[20]  A. Ganser,et al.  Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults , 1988 .

[21]  J. Ritz,et al.  Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. , 1992, Blood.

[22]  N. Brock.  Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. , 1989, Cancer research.

[23]  J. Ledbetter,et al.  Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein. , 1992, Blood.

[24]  A I Goldman,et al.  Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. , 1987, The New England journal of medicine.

[25]  D. Richman,et al.  Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies , 1990, Nature.

[26]  I. Pastan,et al.  Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. , 1989, Cancer research.

[27]  M. Borowitz,et al.  Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1989, Blood.

[28]  M. Greaves.  Differentiation-linked leukemogenesis in lymphocytes. , 1986, Science.

[29]  J. Irvin,et al.  Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. , 1991, Journal of immunological methods.

[30]  T. Vietti,et al.  Clinical evaluation of cyclophosphamide. A new agent for the treatment of children with acute leukemia. , 1962, JAMA.

[31]  R. Bast,et al.  Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4‐hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres , 1991, Cancer.

[32]  R. Youle,et al.  Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. , 1985, Journal of immunology.

[33]  M. Aglietta,et al.  Autologous bone marrow transplantation in acute leukemia. , 1987, Acta haematologica.

[34]  F. Uckun,et al.  Combined immunochemotherapy of human solid tumors in nude mice. , 1987, Cancer research.